Prognosis for esophageal cancer patients depends on the stage of the cancer at diagnosis of course but as the explaination below states, diagnosis is often late and therefore the five year average survival rate is between 13-18%.
A diagnosis of esophageal cancer is not to be taken lightly. My experience as a long-term survivor of a different cancer is that newly diagnosed cancer patients usually follow standard-of-care protocols without considering what is outside the conventional oncology box.
According to the study below, curcumin inhibits the growth of EC. Further, resveritrol and Pterostilbene also inhibit the growth of EC. I am both a cancer survivor and cancer coach. I have lived in complete remission from my “incurable” cancer called multiple myeloma by living an evidence-based, non-toxic anti-MM lifestyle.
Have you been diagnosed with EC? If so, what stage? Let me know if you have any questions.
“Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and the stomach.Symptoms often include difficulty in swallowing and weight loss. Other symptoms may include pain when swallowing, a hoarse voice, enlarged lymph nodes (“glands”) around the collarbone, a dry cough, and possibly coughing up or vomiting blood.
Outcomes are related to the extent of the disease and other medical conditions, but generally tend to be fairly poor, as diagnosis is often late.Five-year survival rates are around 13% to 18%.“
“Background-Curcumin inhibits the growth of esophageal cancer cell lines; however, the mechanism of action is not well understood. It is becoming increasingly clear that aberrant activation of Notch signaling has been associated with the development of esophageal cancer. Here, we have determined that curcumin inhibits esophageal cancer growth via a mechanism mediated through the Notch signaling pathway…
In this study, we show that curcumin treatment resulted in a dose and time dependent inhibition of proliferation and colony formation in esophageal cancer cell lines. Furthermore, curcumin treatment induced apoptosis through caspase 3 activation, confirmed by an increase in the ratio of Bax to Bcl2. Cell cycle analysis demonstrated that curcumin treatment induced cell death and down regulated cyclin D1 levels…
Conclusion-Curcumin is a potent inhibitor of esophageal cancer growth that targets the Notch-1 activating γ-secretase complex proteins. These data suggest that Notch signaling inhibition is a novel mechanism of action for curcumin during therapeutic intervention in esophageal cancers…